What is the 13F Pro Quality Score for OMER?

13F Pro ranks OMEROS CORP (OMER) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OMER's current score at https://13fpro.ai/research/OMER (free sign-up required for the full ranking).

Which hedge funds own the most OMER stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OMER include BlackRock,, WHITEBOX ADVISORS, DeepCurrents Investment Group. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/OMER as soon as new 13F filings post.

Where does 13F Pro source OMER data?

All OMEROS CORP fundamentals and ownership data come directly from SEC EDGAR. OMEROS CORP files with the SEC under CIK 1285819. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OMER in?

OMEROS CORP (OMER) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OMER research updated on 13F Pro?

OMER's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

OMEROS CORP(OMER)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1285819 OMER stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

OMER Stock Analysis & AI Quality Score

AI stock analysis and institutional research for OMEROS CORP (OMER), a Healthcare sector company. OMER is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), OMEROS CORP reports quarterly revenue of $9.9M, net income of $56.1M, free cash flow of $-14.5M. Top institutional holders of OMER by reported 13-F value include BlackRock,, WHITEBOX ADVISORS, DeepCurrents Investment Group, based on the most recent SEC filings. OMER trades on the Nasdaq exchange and files with the SEC under CIK 1285819. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OMER daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OMEROS CORP directly from SEC EDGAR. OMEROS CORP's 13F Pro composite quality score has ranged between 14 and 28 since 2021, currently 14.7 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q1 2026

$9.9M

Net Income

Q1 2026

$56.1M

Free Cash Flow

Q1 2026

$-14.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Net Income

+97.9% YoY

$-3.4MFY 2025

FY22 $47.4MFY23 $-117.8MFY24 $-156.8MFY25 $-3.4M

Operating Income

+26.4% YoY

$-122.8MFY 2025

FY22 $-163.4MFY23 $-164.5MFY24 $-167.0MFY25 $-122.8M

EPS (Diluted)

+98.1% YoY

$-0.05FY 2025

FY22 $0.76FY23 $-1.88FY24 $-2.70FY25 $-0.05

Total Assets

+17.5% YoY

$325.6MFY 2025

FY22 $591.0MFY23 $378.3MFY24 $277.1MFY25 $325.6M

Total Debt

+36378.3% YoY

$68.4MFY 2025

FY22 $315.3MFY23 $213.2MFY24 $187.6KFY25 $68.4M

Op. Cash Flow

+22.0% YoY

$-116.1MFY 2025

FY22 $-86.5MFY23 $74.7MFY24 $-148.8MFY25 $-116.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	—	—	—	—	—	$111.8M
Net Income	$-3.4M +97.9%	$-156.8M -33.1%	$-117.8M -348.5%	$47.4M -75.6%	$194.2M +329.9%	$-84.5M
Operating Income	$-122.8M +26.4%	$-167.0M -1.5%	$-164.5M -0.7%	$-163.4M +5.9%	$-173.6M -173.8%	$-63.4M
EPS (Diluted)	$-0.05 +98.1%	$-2.70 -43.6%	$-1.88 -347.4%	$0.76 -75.6%	$3.12 +282.5%	$-1.71
Total Assets	$325.6M +17.5%	$277.1M -26.8%	$378.3M -36.0%	$591.0M +41.0%	$419.3M +206.1%	$137.0M
Total Debt	$68.4M +36378.3%	$187.6K -99.9%	$213.2M -32.4%	$315.3M +0.6%	$313.5M +98.1%	$158.2M
Operating Cash Flow	$-116.1M +22.0%	$-148.8M -299.1%	$74.7M +186.4%	$-86.5M +21.2%	$-109.7M -82.6%	$-60.1M

AI Insight: OMER Financial Trends

OMER swung to $56M net income in Q1 2026 and returned to positive equity, but operating margins remain deeply negative and cash burn persists.

• Net income reversed from $-31M loss (Q3 2025) to $56M profit (Q1 2026), driven by a one-time gain; operating income still negative at $-17M.

• Total debt fell to $53M (Q1 2026) from $177M (Q3 2025); equity improved to $-63M from $-220M, signaling deleveraging progress.

• Operating cash flow remains negative at $-15M (Q1 2026), with Q1 marking first reported revenue ($10M) after eight quarters of unrecorded sales.

⚠ Operating margin still deeply underwater despite net income swing; $10M quarterly revenue insufficient to cover $-17M operating loss.

⚠ Equity remains negative at $-63M in Q1 2026; sustainability of profitability depends on revenue scale-up from minimal $10M base.

AI Insight: OMER Ratio Trends

OMER swung from deeply negative ROA in Q3 2025 (-66.6%) to strongly positive 78.4% in Q1 2026, but operating margin collapsed to -176.1%.

• ROA reversed sharply from -66.6% in Q3 2025 to +78.4% in Q1 2026, signaling a dramatic swing in profitability.

• Operating margin deteriorated to -176.1% in Q1 2026, indicating severe operational losses offset by non-operating gains.

• TTM ROA stands at 30.1%, masking volatile quarterly swings between -67% and +78% across the trailing twelve months.

⚠ Extreme operating loss (-176.1% margin) suggests non-operating income or one-time items drove Q1 2026 ROA recovery.

⚠ Sustained operational underperformance over 2024–2025 before Q1 2026 rebound requires confirmation of durability.

Get alerted when OMER's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OMEROS CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OMER

BlackRock, Inc.
$56.1M5,309,626 sh
WHITEBOX ADVISORS LLC
$36.4M18,033,000 sh
DeepCurrents Investment Group LLC
$31.9M15,864,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$31.5M2,983,259 sh
D. E. Shaw & Co., Inc.
$27.0M13,380,000 sh
Context Capital Management, LLC
$24.7M12,209,000 sh
UBS Group AG
$24.7M2,340,731 sh
STATE STREET CORP
$20.3M1,919,575 sh
STIFEL FINANCIAL CORP
$19.3M1,831,585 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.5M1,752,323 sh

Fund	Value	Shares
BlackRock, Inc.	$56.1M	5,309,626
WHITEBOX ADVISORS LLC	$36.4M	18,033,000
DeepCurrents Investment Group LLC	$31.9M	15,864,000
VANGUARD CAPITAL MANAGEMENT LLC	$31.5M	2,983,259
D. E. Shaw & Co., Inc.	$27.0M	13,380,000
Context Capital Management, LLC	$24.7M	12,209,000
UBS Group AG	$24.7M	2,340,731
STATE STREET CORP	$20.3M	1,919,575
STIFEL FINANCIAL CORP	$19.3M	1,831,585
GEODE CAPITAL MANAGEMENT, LLC	$18.5M	1,752,323

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OMER on your watchlist

Track score changes the day OMEROS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OMER a good stock to buy?

13F Pro's AI-powered analysis of OMEROS CORP (OMER) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OMER are available on the OMER stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OMER?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OMER. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OMEROS CORP's investment landscape.